Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson B Rodrigues

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 22, 2021
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case SeriesOrly Lipsitz, Joshua D Di Vincenzo, Nelson B Rodrigues, et al.
Brain, Behavior, and Immunity|October 8, 2023
Corrigendum to "COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis" [Brain Behav. Immun. 111 (2023) 211-229]Felicia Ceban, Dana Kulzhabayeva, Nelson B Rodrigues, et al.
Journal of Affective Disorders|May 30, 2021
Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countriesYena Lee, Leanna M W Lui, David Chen-Li, et al.
Journal of Psychiatric Research|June 10, 2022
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysisYazen Alnefeesi, David Chen-Li, Ella Krane, et al.
Harvard Review of Psychiatry|September 7, 2018
Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive DisorderRoger S McIntyre, Yena Lee, Nicole E Carmona, et al.
Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
Bipolar Disorders|May 15, 2020
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorderRoger S McIntyre, Orly Lipsitz, Nelson B Rodrigues, et al.
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.
Scandinavian Journal of Pain|August 30, 2017
Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it)Danielle S Cha, Nicole E Carmona, Rodrigo B Mansur, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 22, 2021
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case SeriesOrly Lipsitz, Joshua D Di Vincenzo, Nelson B Rodrigues, et al.
Brain, Behavior, and Immunity|October 8, 2023
Corrigendum to "COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis" [Brain Behav. Immun. 111 (2023) 211-229]Felicia Ceban, Dana Kulzhabayeva, Nelson B Rodrigues, et al.
Journal of Affective Disorders|May 30, 2021
Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countriesYena Lee, Leanna M W Lui, David Chen-Li, et al.
Journal of Psychiatric Research|June 10, 2022
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysisYazen Alnefeesi, David Chen-Li, Ella Krane, et al.
Harvard Review of Psychiatry|September 7, 2018
Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive DisorderRoger S McIntyre, Yena Lee, Nicole E Carmona, et al.
Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
Bipolar Disorders|May 15, 2020
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorderRoger S McIntyre, Orly Lipsitz, Nelson B Rodrigues, et al.
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.
Scandinavian Journal of Pain|August 30, 2017
Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it)Danielle S Cha, Nicole E Carmona, Rodrigo B Mansur, et al.
Pageof 7